Understanding the Menstrual Hormone Panel: A Clinical Overview
Irregular or absent periods, infertility, recurrent miscarriage, menopausal symptoms, hirsutism, severe acne, unexplained weight changes, galactorrhea, ovarian cysts, insulin resistance, and low libido are among the most common reasons patients seek endocrine evaluation. These presentations rarely trace back to a single cause. Instead, they often reflect disruptions across several interconnected hormonal systems—making a comprehensive menstrual hormone panel an essential tool for accurate diagnosis rather than a single-marker test.
A well-designed sex hormone evaluation, such as the one offered through Poclight's Sex Hormones assay line, is built to capture this complexity. Rather than isolating one gland or one symptom, it evaluates signals across the brain centers, pituitary regulators, adrenal glands, gonads, and placental pathways, supporting a clearer separation between central (hypothalamic/pituitary) dysfunction and peripheral (ovarian, testicular, or adrenal) dysfunction.
Why a Multi-Tier Endocrine Approach Matters
Menstrual irregularities can originate from multiple points along the reproductive axis. A patient with absent periods, for example, may have a problem at the hypothalamus, the pituitary, the ovary, or the adrenal gland—and each origin calls for a different clinical pathway. This is why multi-tier endocrine pathway assessment is a differentiated advantage: by evaluating markers from each level of the axis simultaneously, clinicians can more confidently localize the source of dysfunction instead of relying on sequential, piecemeal testing.
The 9-Analyte Sex Hormone Profile
Poclight's panel is built around nine analytes: β-hCG (Beta Human Chorionic Gonadotropin), LH (Luteinizing Hormone), FSH (Follicle-Stimulating Hormone), AMH (Anti-Müllerian Hormone), Cortisol, Testosterone, Progesterone, E2 (Estradiol), and Prolactin (PRL). Together, these support clinical evaluation of reproductive development, fertility, libido, bone health, metabolic balance, menstrual regulation, and spermatogenesis.
Pregnancy Exclusion Comes First: β-hCG
Before any other hormone is interpreted in a female patient, pregnancy status must be excluded. β-hCG serves this gatekeeping role, confirming or excluding pregnancy and assessing gestational trophoblastic disease. A quantitative β-hCG threshold above 100,000 mIU/mL is diagnostic for gestational trophoblastic disease, while declining or low values may signal ectopic pregnancy, miscarriage, or fetal non-viability.
Gonadotropins: LH and FSH
LH and FSH, both pituitary gonadotropins, are central to distinguishing primary gonadal failure from hypothalamic/pituitary causes. In polycystic ovary syndrome (PCOS), the critical diagnostic ratio is an LH:FSH ratio of 2 or higher. In Klinefelter syndrome, FSH and LH are markedly elevated alongside decreased testosterone, with karyotype 47,XXY serving as confirmatory testing. In hypogonadotropic hypogonadism, both gonadotropins are markedly decreased, and pituitary lesions should be excluded as part of the diagnostic workup. For premature ovarian failure, FSH above 25 IU/mL combined with AMH below 0.5 is diagnostic.
Ovarian Reserve: AMH
AMH offers a direct window into ovarian reserve. An AMH value above 4.7 ng/mL is diagnostic for PCOS, reflecting the elevated follicle pool characteristic of the condition. Conversely, AMH below 0.5 ng/mL—paired with FSH above 25 IU/mL—confirms premature ovarian failure. Because AMH is not routinely informative in males beyond infancy, its clinical utility is concentrated in female reproductive assessment, though it also plays a role in evaluating infant intersex disorders.
Luteal Function: Progesterone
Progesterone evaluates ovulatory and luteal phase adequacy. A decreased progesterone level helps confirm anovulation in PCOS, while a markedly reduced value (↓↓) is characteristic of luteal phase defect. In congenital adrenal hyperplasia, elevated 17-OH progesterone above 10 ng/mL is diagnostic. In contrast, markedly elevated progesterone can be seen with luteal cysts or molar pregnancy, underscoring the need to interpret this marker alongside β-hCG and clinical history.
Estrogen Status: E2
E2 (Estradiol) reflects ovarian and testicular hormone output. It tends to rise with ovarian tumors or PCOS in females and with gynecomastia or testicular tumors in males, while it falls with menopause, ovarian failure, or hypogonadism. A key diagnostic ratio for premature ovarian failure is an FSH:E2 ratio greater than 20, reinforcing the value of interpreting gonadotropins and estrogen together rather than in isolation.
Adrenal Function: Cortisol
Menstrual irregularity is not always confined to the reproductive axis—adrenal dysfunction frequently contributes. Cortisol testing addresses this. Midnight salivary cortisol above 145 ng/dL is diagnostic for Cushing's syndrome, which shows a loss of normal diurnal rhythm. On the opposite end, an AM cortisol below 3 μg/dL is diagnostic for adrenal insufficiency, while cortisol is markedly decreased in congenital adrenal hyperplasia as well.
Androgen and Lactotroph Signals: Testosterone and Prolactin
Testosterone supports assessment of androgen excess or deficiency in both sexes—elevated in PCOS, adrenal tumors, and congenital adrenal hyperplasia, and decreased in hypogonadotropic hypogonadism, primary testicular failure, and Klinefelter syndrome. Prolactin (PRL) detects pituitary lactotroph abnormalities tied to prolactinoma, hypothyroidism, or antipsychotic use; a value above 250 ng/mL suggests macroprolactinoma, and hyperprolactinemia itself is marked by a sharply elevated (↑↑↑) prolactin signal.
Clinical Interpretation Notes and Diagnostic Ratios
Several threshold-based and ratio-based rules recur across this panel and are central to its clinical value:
- PCOS: LH:FSH ratio ≥2; AMH >4.7 ng/mL; decreased progesterone confirming anovulation
- Premature ovarian failure: FSH >25 IU/mL with AMH <0.5; FSH:E2 ratio >20
- Klinefelter syndrome: FSH/LH markedly elevated with decreased testosterone; karyotype 47,XXY confirmatory
- Gestational trophoblastic disease: β-hCG >100,000 mIU/mL
- Cushing's syndrome: midnight salivary cortisol >145 ng/dL with loss of diurnal rhythm
- Adrenal insufficiency: AM cortisol <3 μg/dL
- Congenital adrenal hyperplasia: 17-OH progesterone >10 ng/mL
- Hyperprolactinemia: prolactin >250 ng/mL suggesting macroprolactinoma
These interpretive anchors allow clinicians to move from isolated numbers to actionable differential diagnoses.
Why Poclight's Sex Hormones Panel Supports Better Clinical Decisions
The core differentiated value of Poclight's approach lies in combining nine analytes—β-hCG, LH, FSH, AMH, Cortisol, Testosterone, Progesterone, E2, and Prolactin—into a single clinical framework that spans reproductive, developmental, metabolic, and adrenal evaluation. This structure is relevant across reproductive endocrinology, obstetrics/gynecology, urology, endocrinology, pediatrics, and oncology, reflecting the breadth of conditions that present with menstrual or related reproductive symptoms.
As with any laboratory assay, results from this sex hormone profile should be interpreted following local laboratory standards or guidelines, and findings should always be considered alongside the patient's full clinical picture.
Conclusion
A menstrual hormone panel is only as useful as the breadth and clinical logic behind it. By assessing signals from the brain, pituitary, adrenal glands, gonads, and placenta within one coordinated profile, Poclight's Sex Hormones assay line offers clinicians a structured pathway for evaluating reproductive development, fertility, libido, bone health, metabolic balance, menstrual regulation, and spermatogenesis—supporting more precise identification of where, along the endocrine axis, a patient's dysfunction truly originates.
www.poclight.com
Nanjing Poclight Biotechnology Co., Ltd
